Vimarsana
Biggest News Aggregation in the World

Trial Evaluating Multiple Doses News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Trial Evaluating Multiple Doses. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Trial Evaluating Multiple Doses Today - Breaking & Trending Today

NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting® - Vimarsana News

NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®

Published: November 13, 2023

--As previously reported, the ALPINE 4 study met its primary endpoint, with aldafermin 3 mg demonstrating a statistically significant reduction in Enhanced Liver Fibrosis score compared to placebo...

Source: marketscreener.com
Related Topics:
United StatesMarye RinellaBiopharmaceuticals IncGlobenewswire IncUniversity Of Chicago Pritzker School MedicineSteatotic Liver Disease ProgramClinical Research NetworkExchange CommissionEnhanced Liver FibrosisAmerican AssociationLiver DiseasesTrial Evaluating Multiple DosesCompensated Cirrhosis DueNonalcoholic SteatohepatitisLiver MeetingChicago Pritzker SchoolChief Medical OfficerResearch NetworkPrivate Securities Litigation Reform ActQuarterly ReportStates Securities
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting - Vimarsana News

NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting

Published: November 13, 2023

13.11.2023 - -As previously reported, the ALPINE 4 study met its primary endpoint, with aldafermin 3 mg demonstrating a statistically significant reduction in Enhanced Liver Fibrosis (ELF) score compared to placebo after 48 weeks of treatment- -ELF, an ... Seite 1

Source: wallstreet-online.de
Related Topics:
Marye RinellaUniversity Of Chicago Pritzker School MedicineSteatotic Liver Disease ProgramBiopharmaceuticals IncAmerican AssociationLiver DiseasesTrial Evaluating Multiple DosesCompensated Cirrhosis DueNonalcoholic SteatohepatitisLiver MeetingChicago Pritzker SchoolNgm Biopharmaceuticals ChartGm Biopharmaceuticals KursGm Biopharmaceuticals Aktie